AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9489229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic and therapeutic procedures including blood tests, histologic examinations, instrumental investigations, and surgical interventions.
Number of subjects: 71
Study 8268277 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 228392
Study 8268277 — intervention group
Group type: EXPERIMENTAL
Intervention: Other hepatotoxic drugs
Number of subjects: 228392
Study 8268277 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant exposure to NSAIDs and other hepatotoxic drugs
Number of subjects: 228392
Study 8268277 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin estolate
Number of subjects: 228392
Study 8268277 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa, ampicillin, or NSAIDs
Number of subjects: 228392
Study 3979013 — intervention group
Group type: EXPERIMENTAL
Intervention: Deactivation of cardiopulmonary receptors
Number of subjects: 9
Study 3979013 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of cardiopulmonary receptors
Number of subjects: 9
Study 29703007 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 L PEG alone
Number of subjects: 282
Study 29703007 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG plus 30 mL castor oil
Number of subjects: 282
Study 29703007 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L PEG, 30 mL castor oil and 5 g ascorbic acid
Number of subjects: 282
Study 28216345 — intervention group
Group type: EXPERIMENTAL
Intervention: DSA followed by IVUS
Number of subjects: 100
Study 28216345 — intervention group
Group type: COMPARATOR
Intervention: DSA alone
Number of subjects: 100
Study 25918291 — intervention group
Group type: EXPERIMENTAL
Intervention: Onco‐Move (low‐intensity, home‐based physical activity program)
Number of subjects: 230
Study 25918291 — intervention group
Group type: EXPERIMENTAL
Intervention: OnTrack (moderate- to high-intensity, combined supervised resistance and aerobic exercise program)
Number of subjects: 230
Study 25918291 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 230
Study 23971683 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy and parenting education program
Number of subjects: 0
Study 23971683 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and support
Number of subjects: 0
Study 23971683 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding interventions
Number of subjects: 0
Study 21502292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the lower limb motor cortex
Number of subjects: 0
Study 18639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 47
Study 18639302 — intervention group
Group type: COMPARATOR
Intervention: Pelvic organ prolapse repair alone
Number of subjects: 47
Study 18639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital Distress Inventory
Number of subjects: 47
Study 18639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 47
Study 17069098 — intervention group
Group type: EXPERIMENTAL
Intervention: CRX-675 (2, 20, 100, or 200 microg intranasally)
Number of subjects: 28
Study 17069098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17069098 — intervention group
Group type: EXPERIMENTAL
Intervention: CRX-675 (100 microg)
Number of subjects: 28
Study 12855210 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support, affect, and exercise frequency
Number of subjects: 174
Study 12855210 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy
Number of subjects: 174
Study 12855210 — intervention group
Group type: EXPERIMENTAL
Intervention: Model
Number of subjects: 174
Study 11497500 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin pretreatment
Number of subjects: 10
Study 11497500 — intervention group
Group type: COMPARATOR
Intervention: Laser resurfacing (carbon dioxide or erbium laser)
Number of subjects: 10
Study 9551706 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg t.i.d. pre- and co-treatment with cerivastatin 300 microg
Number of subjects: 12
Study 9551706 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 300 microg alone
Number of subjects: 12
Study 8141156 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 92
Study 8141156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 92
Study 3046554 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate biweekly
Number of subjects: 36
Study 3046554 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of fluphenazine decanoate biweekly
Number of subjects: 36
Study 3046554 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of fluphenazine
Number of subjects: 36
Study 31105027 — intervention group
Group type: EXPERIMENTAL
Intervention: bifrontal tDCS (2 mA, 30min, 22 sessions)
Number of subjects: 52
Study 31105027 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 52
Study 31105027 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study 28972794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparing both the ipsilateral and contralateral parotid glands (Group 1)
Number of subjects: 88
Study 28972794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparing only the contralateral parotid gland (Group 2)
Number of subjects: 88
Study 28972794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparing only the contralateral superficial parotid lobe (Group 3)
Number of subjects: 88
Study 28972794 — intervention group
Group type: COMPARATOR
Intervention: Not sparing any lobe of both parotid glands (Group 4)
Number of subjects: 88
Study 25299703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer restorative system (Equia, GC)
Number of subjects: 59
Study 25299703 — intervention group
Group type: COMPARATOR
Intervention: Microfilled hybrid composite (Gradia Direct Posterior, GC)
Number of subjects: 59
Study 24336419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular measures (positive and negative amplitude‐velocity ratio, mean blink duration, percentage of eye closure, composite score of sleepiness levels - Johns Drowsiness Scale)
Number of subjects: 10
Study 24336419 — intervention group
Group type: EXPERIMENTAL
Intervention: aPVT (10‐min auditory psychomotor vigilance task)
Number of subjects: 10
Study 24336419 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve analysis of ocular measures
Number of subjects: 10
Study 22045373 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 2
Study 22045373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 18079068 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day)
Number of subjects: 208
Study 18079068 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram-Naltrexone combination
Number of subjects: 208
Study 18079068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 17055858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen mixture (FM)
Number of subjects: 72
Study 17055858 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NS)
Number of subjects: 72
Study 12743557 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 400 mg per day for 16 weeks
Number of subjects: 29
Study 12743557 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 29
Study 10560780 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care for hypertensive young urban black men
Number of subjects: 309
Study 10560780 — intervention group
Group type: COMPARATOR
Intervention: Men currently using illicit drugs
Number of subjects: 309
Study 10560780 — intervention group
Group type: COMPARATOR
Intervention: Men currently taking HBP medication
Number of subjects: 309
Study 8909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement of QRS intervals by experienced clinicians
Number of subjects: 231
Study 1872159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured technique
Number of subjects: 100
Study 1872159 — intervention group
Group type: COMPARATOR
Intervention: Sutureless technique
Number of subjects: 100
Study 6354234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 244
Study 6354234 — intervention group
Group type: COMPARATOR
Intervention: Emulsified diazepam (diazemuls)
Number of subjects: 244
Study 29951974 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Adult Family Check-Up (YA-FCU)
Number of subjects: 0
Study 29951974 — intervention group
Group type: COMPARATOR
Intervention: School as usual
Number of subjects: 0
Study 28434694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-posterior approach
Number of subjects: 72
Study 28434694 — intervention group
Group type: COMPARATOR
Intervention: 2-incision approach
Number of subjects: 72
Study 26173911 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient Foley catheter (OFC)
Number of subjects: 101
Study 26173911 — intervention group
Group type: COMPARATOR
Intervention: Inpatient prostaglandin gel (IPG)
Number of subjects: 101
Study 23114520 — intervention group
Group type: EXPERIMENTAL
Intervention: HemoCue
Number of subjects: 314
Study 23114520 — intervention group
Group type: COMPARATOR
Intervention: Reference method (automated haematology analyser)
Number of subjects: 314
Study 21945130 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 10 or 20 mcg/hour
Number of subjects: 1024
Study 21945130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1024
Study 21945130 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 1024
Study 18378940 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief-type question
Number of subjects: 45
Study 18378940 — intervention group
Group type: COMPARATOR
Intervention: Frequency-type question
Number of subjects: 45
Study 18378940 — intervention group
Group type: COMPARATOR
Intervention: Vague question
Number of subjects: 45
Study 17061223 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (lidocaine 4%)
Number of subjects: 28
Study 17061223 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia (lidocaine 4%)
Number of subjects: 28
Study 15599837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Support Program (PSP)
Number of subjects: 276
Study 15599837 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 276
Study 11035828 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (behavior therapy)
Number of subjects: 64
Study 11035828 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention
Number of subjects: 64
Study 8832318 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan with quadriceps contracted
Number of subjects: 14
Study 8832318 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan with quadriceps relaxed
Number of subjects: 14
Study 8832318 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan in 20 degrees of flexion
Number of subjects: 14
Study 1521957 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E (n = 11) - nursed and/or collected as much breast milk as possible prior to maximal exercise
Number of subjects: 23
Study 1521957 — intervention group
Group type: COMPARATOR
Intervention: Group F (n = 12) - did not nurse or collect milk at least two hours prior to maximal exercise
Number of subjects: 23
Study 6498565 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 1.5 mg X kg‐1
Number of subjects: 100
Study 6498565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten per cent lidocaine nasal spray (30 mg in each nostril)
Number of subjects: 100
Study 6498565 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Group A)
Number of subjects: 100
Study 6498565 — intervention group
Group type: COMPARATOR
Intervention: 0.25 per cent phenylephrine nasal spray (0.2 mg in each nostril) (Group C)
Number of subjects: 100
Study 3964592 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who were interviewed beforehand about their anxiety and expectations of pain (Intervention group).
Number of subjects: 102
Study 3964592 — intervention group
Group type: COMPARATOR
Intervention: Patients who were not interviewed beforehand (Control group).
Number of subjects: 102
Study 31987122 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 capsules/day for four weeks
Number of subjects: 41
Study 31987122 — intervention group
Group type: COMPARATOR
Intervention: 400 mL/day of a nutritional drink with the same dose of n‐3 LC PUFA
Number of subjects: 41
Study 29464470 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgical technique (G_B)
Number of subjects: 30
Study 29464470 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with mucoperiosteal flap elevation (G_A)
Number of subjects: 30
Study 27618091 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with added protein (CP) during ICT
Number of subjects: 7
Study 27618091 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with added protein (CP) during RVT
Number of subjects: 7
Study 27618091 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) during ICT
Number of subjects: 7
Study 27618091 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO) during RVT
Number of subjects: 7
Study 24344215 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard risk (SR) - two 4-week intensive elements (protocol III)
Number of subjects: 5060
Study 24344215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk (IR) - protocol III × 3
Number of subjects: 5060
Study 24344215 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk (HR) - protocol III × 3
Number of subjects: 5060
Study 24344215 — intervention group
Group type: COMPARATOR
Intervention: Control - standard treatment
Number of subjects: 5060
Study 22531206 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-atropine
Number of subjects: 38
Study 22531206 — intervention group
Group type: COMPARATOR
Intervention: Saline-atropine
Number of subjects: 38
Study 20695288 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% picaridin spray
Number of subjects: 0
Study 20695288 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% IR3535 spray
Number of subjects: 0
Study 20695288 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% picaridin lotion
Number of subjects: 0
Study 20695288 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% IR3535 lotion
Number of subjects: 0
Study 20695288 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% DEET cream
Number of subjects: 0
Study 20695288 — intervention group
Group type: COMPARATOR
Intervention: Untreated control legs
Number of subjects: 0
Study 18599286 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 reporting
Number of subjects: 82
Study 16733285 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion during labour
Number of subjects: 205
Study 16733285 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion at 2-cm gaping of the uterine cervix
Number of subjects: 205
Study 16733285 — intervention group
Group type: COMPARATOR
Intervention: Traditional delivery (control group)
Number of subjects: 205
Study 12527978 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (GLU)
Number of subjects: 8
Study 12527978 — intervention group
Group type: EXPERIMENTAL
Intervention: Trehalose (TRE)
Number of subjects: 8
Study 12527978 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (GAL)
Number of subjects: 8
Study 10562791 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 45
Study 10562791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms kg‐1
Number of subjects: 45
Study 10562791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms kg‐1
Number of subjects: 45
Study 9148172 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign levodopa preparation combined with carbidopa (25/250)
Number of subjects: 30
Study 9148172 — intervention group
Group type: COMPARATOR
Intervention: Polish levodopa preparation combined with carbidopa (25/250)
Number of subjects: 30
Study 1921737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17 beta‐oestradiol (E2)
Number of subjects: 21
Study 1921737 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg Org OD 14
Number of subjects: 21
Study 1921737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6619028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azlocillin at 6 g/day in three divided doses
Number of subjects: 35
Study 6619028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ticarcillin at 8 g/day in four divided doses
Number of subjects: 35
Study 30409669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self‐Management Program (SDSMP)
Number of subjects: 297
Study 30409669 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 297
Study 30212412 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 741
Study 30212412 — intervention group
Group type: COMPARATOR
Intervention: Colloids
Number of subjects: 741
Study 27099154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX group)
Number of subjects: 50
Study 27099154 — intervention group
Group type: COMPARATOR
Intervention: Propofol-remifentanil (P-R group)
Number of subjects: 50
Study 25043629 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II compression stockings (Venoflex; Thuasne, Levallois‐Perret, France)
Number of subjects: 126
Study 25043629 — intervention group
Group type: COMPARATOR
Intervention: Placebo Jersey
Number of subjects: 126
Study 22064874 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nursing visits (HNV)
Number of subjects: 1154
Study 22064874 — intervention group
Group type: COMPARATOR
Intervention: Office-based care (OBC)
Number of subjects: 1154
Study 20929497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 51
Study 20929497 — intervention group
Group type: COMPARATOR
Intervention: Formula-feeding
Number of subjects: 51
Study 20929497 — intervention group
Group type: EXPERIMENTAL
Intervention: General infant-feeding options
Number of subjects: 51
Study 17667476 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-6.0 mg/day)
Number of subjects: 119
Study 17667476 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 119
Study 17667476 — intervention group
Group type: EXPERIMENTAL
Intervention: Molindone (10-140 mg/day)
Number of subjects: 119
Study 17667476 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 119
Study 17667476 — intervention group
Group type: COMPARATOR
Intervention: N/A (control group not specified)
Number of subjects: 119
Study 16111953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stent placement
Number of subjects: 19
Study 16111953 — intervention group
Group type: COMPARATOR
Intervention: No pancreatic stent placement (control)
Number of subjects: 19
Study 11258785 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) 4.5 g i.v. every 6 hours
Number of subjects: 52
Study 11258785 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (Cl) 900 mg plus aztreonam (Az) 2 g i.v. every 8 hours
Number of subjects: 52
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pepsinogen
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha 1‐AT
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group O
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean age
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset of disease
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal (GI) bleeding
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulcer perforation
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype analysis of alpha 1‐AT
Number of subjects: 32
Study 9230579 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic anomaly
Number of subjects: 32
Study 8190879 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 90
Study 8190879 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Number of subjects: 90
Study 8190879 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 3555943 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 300 mg
Number of subjects: 19
Study 3555943 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (dopamine antagonist)
Number of subjects: 19
Study 3555943 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (alpha-receptor antagonist) and Propranolol (beta-receptor antagonist)
Number of subjects: 19
Study 31009707 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) 3.0 g three times daily for 28 days
Number of subjects: 80
Study 31009707 — intervention group
Group type: COMPARATOR
Intervention: 10% XSLJZT comparator
Number of subjects: 80
Study 28598759 — intervention group
Group type: EXPERIMENTAL
Intervention: Axtair One, an alternating pressure air mattress (APAM)
Number of subjects: 76
Study 28598759 — intervention group
Group type: COMPARATOR
Intervention: Viscoelastic foam mattress (VFM)
Number of subjects: 76
Study 25918964 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 315
Study 25918964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 22746262 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized HIV prevention intervention provided by a medical social worker, including proactive case management for psychosocial problems, counseling about living with HIV, and HIV TRB risk reduction.
Number of subjects: 201
Study 22746262 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 201
Study 22255047 — intervention group
Group type: COMPARATOR
Intervention: Multivariate matching pursuit algorithm with Gabor atoms and support vector machine with a linear kernel
Number of subjects: 1